What the Egrifta SV and Egrifta WR labels state about reconstituting tesamorelin, plus the water, concentration and U-100 units for 5 mg and 10 mg vials.
Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone, approved in the United States to reduce excess abdominal fat in adults with HIV who have lipodystrophy and sold there by Theratechnologies as Egrifta SV and, since 2025, Egrifta WR. It is the one compound in this reconstitution set whose label describes mixing a lyophilized vial, so this page can report a real procedure rather than borrow one. The research-market vial, in 5 mg and 10 mg sizes on this site's calculator preset, has no label; its arithmetic is the same as the label's, and this page does it for both sizes. It recommends nothing.
The tesamorelin calculator runs the same sums for any vial and volume; the tesamorelin dosage page reports the figures and their sources in full; the reconstitution hub indexes every compound.
What the two labels state
|
Egrifta SV |
Egrifta WR |
| Vial |
2 mg lyophilized powder, single-dose |
11.6 mg lyophilized powder, single-patient-use |
|---|
| Diluent |
0.5 mL sterile water for injection |
1.3 mL bacteriostatic water for injection |
|---|
| Stated concentration |
2 mg per 0.5 mL (4 mg/mL) |
8 mg per mL |
|---|
| Labelled dose |
1.4 mg in 0.35 mL, once daily |
1.28 mg in 0.16 mL, once daily |
|---|
| Doses per vial |
one; unused solution discarded |
seven consecutive days |
|---|
| Mixing |
rolled gently for 30 seconds, not shaken; used only if clear, colourless, particle-free |
reconstituted once a week, kept for seven daily doses |
|---|
| Storage |
vial at 20 to 25 °C; solution administered immediately |
vial at 20 to 25 °C before and after mixing; discarded 7 days after mixing |
|---|
| Label revised |
03/2024 |
3/2025 |
|---|
Both labels were read on DailyMed on 2026-09-18.
The label's concentration is not the diluent arithmetic
The Egrifta WR label is a small lesson in what a calculator does and does not know. Dividing 11.6 mg by 1.3 mL gives 8.92 mg/mL, but the label states 8 mg/mL, and 8 mg/mL is the figure its 0.16 mL dose is built on (0.16 mL times 8 mg/mL is 1.28 mg). Dividing 11.6 mg by 8 mg/mL gives 1.45 mL: the finished solution is about 0.15 mL larger than the diluent, because 11.6 mg of powder and its excipients occupy volume once dissolved. The Egrifta SV label, by contrast, states 2 mg per 0.5 mL, treating the powder's volume as negligible for a 2 mg vial.
Every calculator on this site divides by the diluent volume, as the Egrifta SV label does. For milligram-scale research vials the error runs in one direction, a slight overstatement of concentration and so a slight understatement of units, and it is small at 5 or 10 mg; the WR label shows that at 11.6 mg it reaches about a tenth. The reconstitution math walkthrough works the same point through with numbers.
Water volume per vial size
| Vial |
1 mL of water |
2 mL of water |
3 mL of water |
| 5 mg |
5 mg/mL |
2.5 mg/mL |
1.67 mg/mL |
| 10 mg |
10 mg/mL |
5 mg/mL |
3.33 mg/mL |
Units for the label amounts
The amounts are the three the labels and the approval trials name: 2 mg, the dose of the original trials (PMID 20101189); 1.4 mg, the Egrifta SV dose; and 1.28 mg, the Egrifta WR dose; 1 mg is added because vendor and clinic pages cite a 1 to 2 mg range. The two approved concentrations are included as rows so the label's own readings can be checked.
| Concentration |
1 mg |
1.28 mg |
1.4 mg |
2 mg |
| 1.67 mg/mL |
60 units |
76.8 |
84 |
120 |
| 2.5 mg/mL |
40 |
51.2 |
56 |
80 |
| 3.33 mg/mL |
30 |
38.4 |
42 |
60 |
| 4 mg/mL (Egrifta SV) |
25 |
32 |
35 |
50 |
| 5 mg/mL |
20 |
25.6 |
28 |
40 |
| 8 mg/mL (Egrifta WR) |
12.5 |
16 |
17.5 |
25 |
| 10 mg/mL |
10 |
12.8 |
14 |
20 |
The two label rows reproduce the labels exactly: 1.4 mg at 4 mg/mL is 0.35 mL, 35 units, and 1.28 mg at 8 mg/mL is 0.16 mL, 16 units. That agreement is the check that the arithmetic in every other row is the right arithmetic. Only one cell exceeds a syringe, 2 mg at 1.67 mg/mL, and fractional readings appear only at the concentrated end for the odd label amounts.
The 10 mg vial
The most searched question is how a 10 mg vial is mixed. At 1 mL it is 10 mg/mL: 2 mg is 20 units and 1.4 mg is 14 units. At 2 mL it is 5 mg/mL: 40 and 28 units, a concentration that sits between the two approved products' 4 and 8 mg/mL. At 3 mL it is 3.33 mg/mL: 60 and 42 units. Whatever the volume, a 10 mg vial holds five 2 mg amounts or seven 1.4 mg amounts with 0.2 mg left; a 5 mg vial holds two 2 mg amounts with 1 mg left.
Mixing steps, as the label describes them
The Egrifta SV label's sequence is the procedure this page reports, in the label's own order: the sterile water supplied is added to the vial; the vial is rolled gently between the hands for 30 seconds and is not shaken; the solution is inspected for particles and discoloration and used only if clear and colourless; the dose is administered immediately after reconstitution and the unused solution and diluent are thrown away (DailyMed, revised 03/2024). The Egrifta WR label differs in the diluent, bacteriostatic water rather than sterile water, and in keeping the mixed vial for seven daily doses (DailyMed, revised 3/2025). The general procedure for any peptide vial, with supplies and the order of operations, is Medibact's how to reconstitute peptides; this page reports the label and does not rewrite the article.
Storage after mixing
The labels are the only source: Egrifta SV is administered immediately after mixing and the rest discarded, while a reconstituted Egrifta WR vial is kept at 20 to 25 °C and discarded 7 days after mixing (DailyMed, read 2026-09-18); a research vial has no label, and storage is covered by Medibact's how to store peptides.
Every label figure carries a route (subcutaneous, into the abdomen), a frequency (once daily), a population (adults with HIV and lipodystrophy) and an endpoint (visceral adipose tissue). The trial behind the original 2 mg dose randomised 404 such patients, reported a 10.9% fall in visceral fat at six months against 0.6% on placebo, about 18% at 12 months, and a rapid return of fat in those switched to placebo (PMID 20101189). ClinicalTrials.gov listed 24 tesamorelin studies and PubMed 23 randomised-trial records on 2026-09-18. The 1 to 2 mg per day range on vendor and clinic pages (read 2026-09-18) is the label and trial figure repeated, not a separate source. The tables convert milligrams to units and do nothing else. The mechanism, evidence and sourcing belong to Medibact's tesamorelin guide, and the pairing most searches attach to it is on this site's tesamorelin and ipamorelin stack page.
Sources and dates
Opened 2026-09-18: DailyMed, the Egrifta SV label (revised 03/2024) and the Egrifta WR label (revised 3/2025); PubMed record 20101189 (Falutz and colleagues, 2010); ClinicalTrials.gov v2 API (24 registrations); MedlinePlus, "Giving an insulin injection" (reviewed 2024-07-21); vendor and clinic pages for the circulating range. Vial sizes are the ones the calculator preset uses.
This page does not recommend a dose, a water volume, a syringe or a schedule, and it does not say what any figure means for a particular person. It reports what two labels and one trial state, and converts milligrams into millilitres and units.
